Sugi Predict

Sugi Predict / Compounds / SCHEMBL783391

SCHEMBL783391

SCHEMBL783391

Cc1ccncc1-c1ccc2oc(=O)n(C)c2c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 7/20 0.45
▸ CYP11B1 P15538 6/20 0.45
▸ GPR55 Q9Y2T6 2/20 0.43
▸ ABL1 P00519 3/20 0.41
▸ PRMT5 O14744 1/20 0.40
▸ WDR77 Q9BQA1 1/20 0.40
▸ KCNJ1 P48048 4/20 0.39
▸ JAK1 P23458 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL742976 0.84 GPR55 (0.41) CYP11B2GPR55KCNJ1MEN1LMNA
SCHEMBL783451 0.83 GPR55 (0.40) CYP11B2CYP11B1GPR55KCNJ1
SCHEMBL782504 0.83 CYP11B2 (0.47) CYP11B2CYP11B1GPR55ABL1KCNJ1
SCHEMBL744470 0.82 GPR55 (0.44) CYP11B2GPR55KCNJ1
SCHEMBL782551 0.82 CYP11B2 (0.40) CYP11B2GPR55KCNJ1
SCHEMBL782297 0.80 GPR55 (0.42) CYP11B2GPR55KCNJ1
SCHEMBL782662 0.79 KCNJ1 (0.42) CYP11B2GPR55KCNJ1
SCHEMBL783338 0.79 KCNJ1 (0.45) CYP11B2GPR55KCNJ1
SCHEMBL782951 0.78 CYP19A1 (0.55) CYP11B2CYP11B1GPR55
SCHEMBL782710 0.78 CYP11B2 (0.54) CYP11B2GPR55KCNJ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430018-B1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2013-07-03 — — EP disclosed
EP-2430018-B1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS NOVARTIS AG (CH) 2013-07-03 — — EP disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-8455522-B2 Benzoxazolone derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-06-04 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071514-A1 BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS CYP11B2, CYP11B1, CYP21A2 CYP11B2 1/4885CYP11B1 2/4885GPR55 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.